Position in PTCT
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$44,112,948
+$7,046,216 QoQ
Shares Held
647,482
+32.7% QoQ
Ownership
0.781%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in PTCT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Boston Partners holds $301,190,357 across 5 Biotechnology names. PTCT ranks #2 (14.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
2,683,683 | $173,446,430 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
This page
|
647,482 | $44,112,948 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
1,711,573 | $42,378,546 | |
| 4 | INVA |
Innoviva, Inc.
|
1,718,867 | $40,049,601 | |
| 5 | HRMY |
Harmony Biosciences Holdings, Inc.
|
42,943 | $1,202,832 |
All Filings in PTCT
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $44,112,948 | 647,482 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $37,066,732 | 487,977 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $22,195,319 | 361,664 | Shares | Defined | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||